Nabi Biopharmaceuticals Completes Sale of Nabi Biologics to ...(irdparties to fund develop and manufactu...),Health

Date:12/4/2007

ird parties to fund, develop, and manufacture our pipeline products, including NicVAX and our gram-positive infections products; obtain successful clinical trial results; realize anticipated cost savings related to job elimination due to greater than anticipated severance-related costs or other factors; maintain a sufficient cash balance and generate sufficient cash flow from milestone or royalty payments to fund our development and commercialization activities; attract and maintain the human and financial resources to bring to market products in development; depend upon third parties to manufacture or fill our products; achieve approval and market acceptance of our products; enter into and maintain arrangements with third parties to market and sell our products; manufacture NicVAX or other products; comply with reporting and payment obligations under government rebate and pricing programs; raise additional capital on acceptable terms, or at all; and re-pay our outstanding convertible senior notes when due. Many of these factors are more fully discussed, as are other factors, in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2006 and our Quarterly Report on Form 10-Q for the quarter ended September 29, 2007 filed with the Securities and Exchange Commission.

'/>"/>

SOURCE Nabi Biopharmaceuticals Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine news :

1. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
2. Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting
3. Eligard(R) six-month formulation successfully completes European approval procedure
4. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
5. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
6. Symmetry Medical Completes Acquisition Of Specialty Surgical Instruments
7. GSI Securitization Completes Merger and Domicile Transfer
8. Medical Services International Inc. Completes Testing for European Union (EU) Application
9. Inverness Completes Acquisition of Cholestech
10. Billians HealthDATA Completes Comprehensive Long Term Care Database Update
11. Synova Completes Sale of $3.3 Million in Senior Convertible Notes and Warrants